Replies to post #1777 on Idenix Pharmaceuticals (IDIX)

[DewDiligence]

IDIX ReadMeFirst

[Updated for disclosures at 9/11/07 Bear Stearns
webcast and the rumor about restructuring the
relationship with NVS. (The webserver that hosts
the image files referenced here is temporarily down;
these images will not download until the webserver
is back in operation. Apologies for the inconvenience.)]


What is IDIX’s business all about?
http://www.idenix.com/about Capsule version
http://tinyurl.com/2uvynn Detailed version
#msg-22779388 Pipeline chart


Valuation and finances
#msg-22707854 Valuation is preposterously cheap
#msg-21777418 2Q07 results and cash-burn-guidance for 2007
#msg-22709801 Reasons for high cash burn
#msg-21248770 Economics of Tyzeka collaboration with NVS
#msg-22713624 Rumor about restructuring the relationship
#msg-21856488 Hypothetical cash-flow analysis


Upcoming events
#msg-22774317 2007-2008 news flow


Officers, directors, and major shareholders
http://www.idenix.com/about/leadership Capsule résumés of executive officers (click on each name)
http://tinyurl.com/2fp2gz Capsule résumés of directors (page 5-6)
http://tinyurl.com/23shp3 Major shareholders
#msg-22707884 Protection from hostile takeover
#msg-11075184 CEO bought shares at $9.13


Tyzeka/Sebivo commercial program in HBV
#msg-14283481 Approval in US
#msg-19227779 Approval in EU
#msg-17536458 Approval in China
#msg-16968726 Prevalence of HBV by country
#msg-21746191 US market is expanding rapidly
#msg-22707869 European market is large and poorly penetrated
#msg-21401098 Current Hepsera sales
#msg-21567297 Current Baraclude sales
#msg-21567340 Baraclude sales ramp 2005-present
#msg-22771678 2007 Tyzeka sales guidance
#msg-21358606 Why a slow sales ramp for new HBV drugs?
#msg-21388028 Bearish opinion by ‘gofishmarko’
#msg-22779609 Tyzeka weekly scripts


Tyzeka clinical data
#msg-14377860 Two-year data from GLOBE trial
#msg-22771520 Tyzeka studies in progress
#msg-12271882 Tyzeka resistance data
#msg-14404551 Tyzeka’s efficacy comparable to Baraclude’s (1)
#msg-18389527 Tyzeka’s efficacy comparable to Baraclude’s (2)
http://www.fda.gov/cder/foi/label/2006/022011lbl.pdf FDA product label


Competitive landscape in HBV: general
#msg-21746191 Tyzeka competition
#msg-21745093 Nucleoside vs nucleotide in HBV
#msg-21652956 Prices of HBV drugs


Competitive landscape in HBV: Baraclude
#msg-22555240 Baraclude studies in progress
#msg-21652925 Baraclude’s black-box warning for HIV/HBV co-infection
#msg-21678537 Size of HIV/HBV co-infection market
#msg-21678801 Tyzeka’s edge in pre-menopausal women
#msg-21567297 Current Baraclude sales
#msg-21567340 Baraclude sales ramp 2005-present


Competitive landscape in HBV: Hepsera
#msg-21746191 Hepsera’s efficacy is inferior to Tyzeka’s
#msg-21460468 Gilead to cease promotion when Viread approved
#msg-21401098 Current Hepsera sales


Competitive landscape in HBV: Viread/Truvada
#msg-20743204 Phase-3 Viread data
#msg-22555241 Viread/Truvada studies in progress
#msg-21745093 Nucleoside vs nucleotide in HBV
#msg-20250616 Viread is structurally similar to Hepsera


Competitive landscape in HBV: Clevudine
#msg-21955710 US phase-3 program
#msg-14328142 Clinical results from Korea (PR)
#msg-14372893 Clinical results from Korea (table)
#msg-20216885 Clevudine, Tyzeka are structurally similar (diagram)
#msg-20218516 Clevudine, Tyzeka are structurally similar (commentary)


Development program in HIV
#msg-17527610 IDX-899 selected as lead HIV candidate
#msg-22596568 Sustiva (industry-leading NNRTI) sells almost $1B/yr
#msg-21895680 Importance of once-daily dosing


Development program in HCV
http://www.idenix.com/hepc/drug Description of HCV program
#msg-21197309 NM283 development discontinued


Educational Links
http://www.idenix.com/about/media/Glossary_of_terms.pdf
http://www.idenix.com/hepb/about
http://www.idenix.com/hiv/about
http://www.idenix.com/hepc/about
http://www.hivandhepatitis.com
http://www.hepfi.org